匯友生命科學(08088.HK)年度虧損收窄80.91%至1.46億港元
格隆匯3月20日丨匯友生命科學(08088.HK)公佈,截至2019年12月31日止年度,實現收入1173.9萬港元,同比減少39.05%;公司擁有人應占年度虧損1.46億港元,同比收窄80.91%;每股基本虧損26.9港仙,無派息。
集團已出售集團前全資附屬公司滙友資產管理有限公司。出售滙友資產管理後,主要營運決策者(即公司執行董事)識別集團僅有一個經營分部,即策略投資分部。截至2019年12月31日止年度,集團並無呈列分部資料獨立分析,原因為集團超過90%收益、資產及負債均與策略投資業務有關。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.